InMed Pharmaceuticals Inc. (CNW Group/InMed Pharmaceuticals Inc.)

InMed Submits Clinical Trial Application to Evaluate INM-755

InMed Pharmaceuticals Inc. announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a second Phase 1 human clinical trial for INM-755 in healthy volunteers.

755-102-HV is a randomized, double-blind, vehicle-controlled, Phase 1 study designed to evaluate the safety and tolerability of INM-755 cream applied daily on epidermal wounds in healthy volunteers. Two strengths of INM-755 cream will be evaluated in 8 adult subjects over a 14-day treatment period.

“This second Phase 1 trial represents another important step towards efficacy trials with INM-755,” said Alexandra Mancini, Senior Vice President of Clinical and Regulatory Affairs. “The review of this CTA application will proceed as usual despite the restrictions in place in the Netherlands for the COVID-19 pandemic. Once the CTA is approved, enrollment will begin as soon as possible after those restrictions are lifted.”